Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.55 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298586 | 0.88 | IDO1 (0.64) | SIGMAR1SLC6A2SLC6A4SLC6A3HAO1 | |
| SCHEMBL28128266 | 0.82 | SIGMAR1 (0.60) | TDP1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1040242 | 0.81 | CALM1 (0.48) | TSHRMAPK1TDP1SIGMAR1SLC6A2 | |
| SCHEMBL744471 | 0.81 | IDH1 (0.68) | CALM1IDH1CYP3A4 | |
| SCHEMBL27589093 | 0.81 | CALM1 (0.48) | TSHRMAPK1TDP1SIGMAR1SLC6A2 | |
| SCHEMBL9462466 | 0.81 | IDH1 (0.68) | TSHRTDP1CALM1IDH1CYP3A4 | |
| SCHEMBL253442 | 0.81 | CALM1 (0.48) | TSHRMAPK1TDP1SIGMAR1SLC6A2 | |
| SCHEMBL6351215 | 0.81 | CYP3A4 (0.80) | TSHRMAPK1TDP1CALM1IDH1 | |
| SCHEMBL1043112 | 0.81 | CALM1 (0.48) | TSHRMAPK1TDP1SIGMAR1SLC6A2 | |
| SCHEMBL11587862 | 0.80 | ESR1 (0.61) | SLC6A2SLC6A4SLC6A3HAO1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | disclosed |
| US-4336397-A | 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis | MERCK & CO., INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4260506-A | Hydraulic pressure device utilizing biodegradable halogenated diphenyl methanes | MONSANTO COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | TSHR 3065/4885MAPK1 3177/4885TDP1 4412/4885 |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1I, CACNA1C, ORAI1 | TSHR 3566/4885MAPK1 2242/4885TDP1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.